Anti-apoptotic effects of valproic acid treatment on dopaminergic neuronal loss in a 6-hydroxydopamine model of Parkinson’s disease in rats
Open Access
- 24 May 2022
- journal article
- research article
- Published by Anadolu Klinigi Tip Bilimleri Dergisi in Anadolu Kliniği Tıp Bilimleri Dergisi
- Vol. 27 (2) , 194-203
Abstract
Aim: Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons resulting in deterioration of motor activity in patients. Currently, available therapies including Levodopa (L-DOPA) are more geared toward the treatment of symptoms. Therefore, developing effective neuroprotective therapies is needed. Valproic acid (VPA) has shown potent neuroprotective effects on dopamine (DA) neurons in various brain regions. The aim of this study is to investigate whether VPA attenuates the neuronal loss when co-treated with L-DOPA in a 6-hydroxydopamine (6-OHDA) induced PD model in rats.Methods: Male Wistar Albino rats received intranigral injection of 6-OHDA unilaterally. Twelve days later rats received either saline, L-DOPA, VPA, or L-DOPA+ VPA for 9 days. To determine whether rats had dopaminergic neuronal loss apomorphine-induced rotation test was used. Immunohistochemical analyses were performed in the Substantia Nigra pars compacta (SNpc) by measuring the tyrosine hydroxylase (TH) positive neurons and the apoptotic neurons.Results: 6-OHDA injection showed clinically impairment of the motor function with histologically significant damage to the dopaminergic neurons. VPA administration combined with L- DOPA protected neurons in SNpc by increasing the TH positive neurons and by decreasing the apoptotic neurons. L-DOPA given as a monotherapy, on the other hand, was ineffective on these parameters.Conclusion: Our experiments demonstrated that VPA had a neuroprotective effect when used with L-DOPA in the PD rat model.Keywords
Funding Information
- Yeditepe Üniversitesi (120800002)
This publication has 19 references indexed in Scilit:
- Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned ratBehavioural Pharmacology, 2012
- Animal models of Parkinson's diseaseParkinsonism & Related Disorders, 2012
- Valproic Acid–Induced Parkinsonism in the Elderly: A Comprehensive Review of the LiteratureThe American Journal of Geriatric Pharmacotherapy, 2011
- Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's diseaseNeuroscience, 2011
- Valproic acid improves outcome after rodent spinal cord injury: Potential roles of histone deacetylase inhibitionBrain Research, 2011
- The complex language of chromatin regulation during transcriptionNature, 2007
- RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent TranslationJournal of Biological Chemistry, 2007
- Epidemiology of Parkinson's diseaseThe Lancet Neurology, 2006
- Nature of Inhibition of Mitochondrial Respiratory Complex I by 6‐HydroxydopamineJournal of Neurochemistry, 1996
- 6-hydroxy-dopamine induced degeneration of central monoamine neuronsEuropean Journal of Pharmacology, 1968